Twist Bioscience Stock vs Competition: Who Wins?
Twist Bioscience’s stock saw mixed 12-month returns, but how does it measure up against peers like Illumina and Thermo Fisher in the dynamic synthetic biology space? A closer look reveals strong revenue growth, outpacing many, yet significant unprofitability with negative operating and free cash flow margins. Its negative P/E ratio reflects this earnings challenge, contrasting with profitable peers. While growth is robust, sustained profitability remains a critical hurdle against more established industry players.
- TWST’s -34.4% operating margin shows heavy growth investment, trailing ILMN’s 18.6% as it nears profitability post-GRAIL divestiture.
- TWST’s 18.6% revenue growth, fueled by synthetic biology and AI drug discovery, outpaces peers like DNA and ILMN.
- TWST’s 10.6% stock drop and -37.3 P/E reflect investor concerns on current losses, despite growth and FY26 EBITDA breakeven targets.
Here’s how Twist Bioscience stacks up across size, valuation, and profitability versus key peers.
| TWST | DNA | ILMN | TMO | CDXS | TXG | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 2.9 | 0.5 | 21.6 | 219.9 | 0.1 | 2.5 |
| Revenue ($ Bil) | 0.4 | 0.2 | 4.3 | 43.7 | 0.1 | 0.6 |
| PE Ratio | -37.3 | -1.5 | 30.7 | 33.5 | -2.0 | -32.8 |
| LTM Revenue Growth | 18.6% | -17.1% | -2.3% | 3.2% | -17.9% | 1.9% |
| LTM Operating Margin | -34.4% | -184.5% | 18.6% | 18.4% | -112.7% | -22.0% |
| LTM FCF Margin | -22.1% | -103.6% | 23.3% | 14.0% | -116.5% | 12.7% |
| 12M Market Return | -10.6% | -31.4% | 6.3% | -2.3% | -65.6% | 33.0% |
For more details on Twist Bioscience, read Buy or Sell TWST Stock. Below we compare TWST’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| TWST | 18.6% | 20.3% | 27.7% | 20.4% | |
| DNA | -17.1% | – | -9.7% | -47.4% | 52.2% |
| ILMN | -2.3% | – | -2.9% | -1.7% | 1.3% |
| TMO | 3.2% | – | 0.1% | -4.6% | 14.5% |
| CDXS | -17.9% | – | -15.4% | -49.4% | 32.3% |
| TXG | 1.9% | – | -1.3% | 19.8% | 5.3% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| TWST | -34.4% | -36.2% | -56.2% | -84.4% | |
| DNA | -184.5% | – | -214.8% | -305.5% | -462.4% |
| ILMN | 18.6% | – | 13.7% | -4.9% | 7.7% |
| TMO | 18.4% | – | 18.0% | 17.1% | 18.9% |
| CDXS | -112.7% | – | -98.3% | -78.1% | -22.9% |
| TXG | -22.0% | – | -31.9% | -33.0% | -32.5% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| TWST | -37.3 | -24.4 | -12.9 | -10.2 | |
| DNA | -1.5 | – | -0.8 | -0.5 | -1.3 |
| ILMN | 30.7 | – | -17.1 | -18.2 | -4.8 |
| TMO | 33.5 | – | 34.9 | 33.5 | 29.9 |
| CDXS | -2.0 | – | -1.8 | -4.3 | -5.9 |
| TXG | -32.8 | – | -10.8 | -6.6 | -38.4 |
Still not sure about TWST stock? Consider portfolio approach.
The Best Investors Think In Portfolios
Individual stocks can soar or tank but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside and mitigate the downside associated with any individual stock.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.